about
RNA Secondary Structure Modulates FMRP's Bi-Functional Role in the MicroRNA PathwayAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderAltered Neuronal and Circuit Excitability in Fragile X Syndrome.Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis)Altered Translational Control of FMRP on Myelin Proteins in Neuropsychiatric DisordersFragile X syndrome: A review of clinical managementAdvanced technologies for the molecular diagnosis of fragile X syndromeFragile X Syndrome: Prevalence, Treatment, and Prevention in ChinaFragile X targeted pharmacotherapy: lessons learned and future directions.Metabotropic Glutamate Receptor and Fragile X Signaling in a Female Model of Escalated Aggression.Psychiatric gene discoveries shape evidence on ADHD's biologyTowards a Better Molecular Diagnosis of FMR1-Related Disorders-A Multiyear Experience from a Reference Lab.Endocrine Dysfunction in Female FMR1 Premutation Carriers: Characteristics and Association with Ill Health.Human pluripotent stem cell models of Fragile X syndrome.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.An update on the comorbidity of ADHD and ASD: a focus on clinical management.A general description for Chinese medicine in treating premature ovarian failure.Autism Symptoms in Fragile X Syndrome.Fragile X syndrome: an overview and update of the FMR1 gene.The Number of Parvalbumin-Expressing Interneurons Is Decreased in the Medial Prefrontal Cortex in Autism.In Silico Analysis of FMR1 Gene Missense SNPs.Beware of manipulations on the genome: epigenetic destabilization through (foreign) DNA insertions.Cell Type-Specific mRNA Dysregulation in Hippocampal CA1 Pyramidal Neurons of the Fragile X Syndrome Mouse Model.Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.Fragile X syndrome and fragile X-associated disorders.Recent advances in assays for the fragile X-related disorders.Stem Cell Technology for (Epi)genetic Brain Disorders.Gene-set analysis shows association between FMRP targets and autism spectrum disorder.Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.Identification of microsatellite markers <1 Mb from the FMR1 CGG repeat and development of a single-tube tetradecaplex PCR panel of highly polymorphic markers for preimplantation genetic diagnosis of fragile X syndrome.Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach.Fragile X mental retardation protein controls ion channel expression and activity.Autism genes: the continuum that connects us all.Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome.
P2860
Q26747489-E514FE5A-ADC3-4B0B-9E52-DA2F58808C38Q26781265-B920B62F-01B7-4C36-933A-AFC24BD5B156Q26796317-C1D9FADD-E0ED-4AC0-8D86-339AF3692866Q26801165-2A6E7FEC-6956-4D21-911E-A4995C808A76Q28069747-A9A1E58C-A015-4517-82C9-A72234C2C78EQ28076950-37830D28-B513-4215-81E1-E2622AB29EB2Q28087781-5C76E382-025A-4274-AB9B-2FCBD20365E3Q33766106-B72C093A-520E-4C4B-ABF9-D54011FFE78FQ33785983-BA31A431-37F1-4D4D-89CC-E40A8BB837EBQ36554711-48B3EB98-C195-4CBC-9E41-B9469A5D95FBQ36763139-AFF31AC0-950A-4862-BE1F-E96B55EC443DQ37296765-89B4CD6C-F9D5-4A85-B79B-B00B9D4574FFQ37449715-FDC97A29-DE6F-4926-9561-B539487201C8Q38660520-20B954EB-667D-40B7-A1DD-CBD69177E8D7Q38726962-FFB098D4-56C2-49AD-A43F-5A8209509ACAQ38859181-114E8137-2CBC-470B-8072-B02B01081374Q38916468-58475C63-17F3-4616-B467-2B369D755507Q39164979-5FB30AF0-2BC9-4539-B788-F829061118C9Q39375314-B5FEF229-2721-45BC-88AE-C0B23BF86400Q39375765-EB1EBDB6-2A4E-4BDB-90E2-CAC342637487Q39963085-6BD071D0-4555-4994-BE00-798C70D6B7E3Q39994872-9F11E392-C5BB-4CAB-B76E-FF712A2A9303Q40842090-804B0D1E-EE6F-4D1E-8029-547C64160380Q46122623-C5911414-A264-47D1-A8A2-562AB65B789AQ47112165-3A4AEC22-FFFD-4C11-90F7-8490A8643CC7Q47140616-46440D9B-3FF5-4562-9561-65D21C901390Q47630636-EECD0BCF-FD9F-4FBF-804B-FD44E7D44980Q47718746-FBD063C3-447B-46D4-B5E5-BA8DAA025397Q47745129-E8E374F0-40B0-40EE-A64A-C5340F7CB8CEQ47795409-2D465C7E-BB96-4A7B-A2F8-E3D560EF9B56Q48267538-90BECDC3-D277-43F8-A654-9C99644C6403Q48513662-353EF0C8-238D-474E-BF09-6AA2315BFC17Q48915976-6414443F-587E-4D4A-B503-ABCD7A6C75AFQ50313938-BFE3CA5C-DD68-42EE-836E-6D3DAF42BF16Q55155951-5362E022-1CF2-45FA-AA52-1161131D872BQ55386099-0C804814-7468-458C-9D26-48C1E29467F8
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Fragile X spectrum disorders
@ast
Fragile X spectrum disorders
@en
Fragile X spectrum disorders
@nl
type
label
Fragile X spectrum disorders
@ast
Fragile X spectrum disorders
@en
Fragile X spectrum disorders
@nl
prefLabel
Fragile X spectrum disorders
@ast
Fragile X spectrum disorders
@en
Fragile X spectrum disorders
@nl
P2093
P2860
P3181
P356
P1476
Fragile X spectrum disorders
@en
P2093
P2860
P304
P3181
P356
10.5582/IRDR.2014.01022
P407
P577
2014-11-01T00:00:00Z